Daniel G. Welch
Chairman, Chief Executive Officer and President
InterMune, Inc.

Mr. Welch has served as our Chairman of the Board since May 2008. Mr. Welch has served as our Chief Executive Officer and President since September 2003. From 2002 to 2003, Mr. Welch was Chairman and CEO of Triangle Pharmaceuticals, a biopharmaceutical company, which was acquired by Gilead in 2003. From 2000 to 2002, Mr. Welch was President of Biopharmaceuticals at Elan Corporation. During his tenure at Elan, he was responsible for U.S. commercial operations, the international subsidiaries, the R&D function and the diagnostics businesses. From 1987 to 2000, Mr. Welch served in senior management roles at Sanofi-Aventis and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi-Aventis, he led the successful worldwide launches of Plavix®, Eloxatin® and Avapro® as Vice President of Worldwide Marketing and he served as COO of the U.S. business. Prior to joining Sanofi-Aventis, Mr. Welch was with American Critical Care, a division of American Hospital Supply. Mr. Welch is a member of the Board of Directors of Seattle Genetics, Inc, Corium International, Inc., and BayBio, the bay-area biotech industry association. He holds an M.B.A. from the University of North Carolina and a B.B.A. from the University of Miami.